BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29055471)

  • 1. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
    Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
    Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
    Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J; Wang LN; Zhan S; Xia Y
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.
    Cohan S; Kappos L; Giovannoni G; Wiendl H; Selmaj K; Havrdová EK; Rose J; Greenberg S; Phillips G; Ma W; Wang P; Lima G; Sabatella G
    Mult Scler; 2018 Dec; 24(14):1883-1891. PubMed ID: 28984179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
    J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
    BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
    Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
    Havrdova E; Giovannoni G; Stefoski D; Forster S; Umans K; Mehta L; Greenberg S; Elkins J
    Mult Scler; 2014 Apr; 20(4):464-70. PubMed ID: 24022270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
    Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
    Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J; Wang L; Zhan SY; Xia Y
    Cochrane Database Syst Rev; 2012 Apr; (4):CD008127. PubMed ID: 22513956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclizumab: A Review in Relapsing Multiple Sclerosis.
    Shirley M
    Drugs; 2017 Mar; 77(4):447-458. PubMed ID: 28211007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Benedict RH; Cohan S; Lynch SG; Riester K; Wang P; Castro-Borrero W; Elkins J; Sabatella G
    Mult Scler; 2018 May; 24(6):795-804. PubMed ID: 28485186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
    Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
    Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.